Telaglenastat

Generic Name: Telaglenastat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₄F_₃N_₇O_₃S

CAS Number: 1439399-58-2

Unique Ingredient Identifier: U6CL98GLP4

Background: Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force

Osteosarcoma, the most common bone tumor in young individuals, has seen no outcome improvements for decades due to its complexity and lack of targeted drugs. The New Agents for Osteosarcoma Task Force identified promising agents, with multitargeted tyrosine kinase inhibitors prioritized for frontline evaluation in upcoming trials.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy